The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
March 5th 2024
Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products.
December 31st 2023
Saudi Researchers Call for Greater Use of Trastuzumab Biosimilars to Offset Breast Cancer Costs
September 2nd 2021Switching from Herceptin (reference trastuzumab) to trastuzumab biosimilars could significantly reduce direct medication costs attributed to breast cancer management in Saudi Arabia, researchers concluded.
Read More
Dr Neal Dave: Are Physicians Excited for More Biosimilars to Enter the Oncology Space?
August 27th 2021Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.
Watch
Study Confirms Overall Survival in DLBCL Is Comparable Between Rituximab Biosimilars and Rituxan
August 24th 2021In comparison with reference rituximab (Rituxan), the use of rituximab biosimilars in combination therapy produced similar 3-year overall survival among patients with large-B-cell lymphoma (DLBCL), investigators concluded.
Read More
Site of Care Potentially Limits Cost Savings From Biosimilars
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.
Read More
Dr Neal Dave Explains Why Biosimilars Should Be Favored Over Reference Products
August 20th 2021Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
Watch
Switching to a Pegfilgrastim Biosimilar May Facilitate Access to Chemotherapy
August 19th 2021Switching patients from reference pegfilgrastim to a biosimilar could lead to substantial cost savings, with potential to offset the cost of and allow for greater access to chemotherapy treatment, investigators concluded.
Read More
Real-world Evidence Shows Good Acceptance of Rituximab Biosimilar for NHL, CLL
August 5th 2021In one of the first studies to examine real-world evidence on rituximab biosimilars in the United States, investigators found that many providers treating patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are regularly prescribing a biosimilar rituximab.
Read More
Alliance for Patient Access Releases Paper on Biosimilar Best Practices in Oncology
July 26th 2021Two oncologists dive into the reasons behind physician hesitancy and unwillingness to prescribe biosimilars to patients with cancer and make suggestions on how to increase confidence in these agents.
Read More
Originator Drugs Experience Price Drops When Multiple Biosimilars Are Added to Reimbursement Lists
July 15th 2021The price of reference products reduced each time a new biosimilar was added to a drug program’s reimbursement list, supporting the notion that reimbursing biosimilars creates more competition and lowers drug costs, according to a Polish study.
Read More
Patient Advocacy Organizations Join Forces to Endorse BIOSIM Act
July 7th 2021Twenty-eight patient advocacy groups wrote a letter pledging endorsement of the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, a bill aimed at increasing reimbursement and incentivizing prescriptions for biosimilars.
Read More
Dr Ivo Abraham: Biosimilar Pegfilgrastims vs Neulasta Onpro Utilization
June 24th 2021Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, talks about the role that the pandemic has played in the struggle between biosimilar pegfilgrastims and the on-body injector version of the reference product.
Watch
Xcenda Report Shows Biosimilar Competition Lowered Drug Prices of Reference Oncology Biologics
June 23rd 2021A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.
Read More
Dr Ivo Abraham on How Neulasta Onpro Is Impacting the Biosimilars Space
June 18th 2021Ivo Abraham, PhD, RN, a professor in the Department of Pharmacy Practice at University of Arizona Health Sciences, talks about the results from his cost-efficiency studies and how Amgen’s Onpro pegfilgrastim device has affected cancer care and costs.
Watch
Dr Ivo Abraham Details the Current State of G-CSF Biosimilars in the US
June 11th 2021Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, discusses the current state of the granulocyte-colony stimulating factor (G-CSF) sector of the biosimilar market.
Watch
High-Concentration Adalimumab Biosimilar Yields Positive 1-Year Data
June 2nd 2021Celltrion Healthcare’s high-concentration adalimumab biosimilar demonstrated comparable safety, efficacy, and immunogenicity profiles to the reference product for up to a year, providing further evidence supporting use of the product.
Read More
Dr Sonia Oskouei Differenciates Pharmacist Concerns From Physicians' Regarding Biosimilars
June 1st 2021Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, talks about the differences between provider and pharmacist concerns and whether health organizations giving more power to pharmacists causes conflict with physicians.
Watch
Dr Sonia Oskouei Discusses the Potential for the First Interchangeable Biosimilar
May 26th 2021Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, explains the ramifications that interchangeability designations will have on biosimilars and when we might see the first interchangeable biosimilar in the United States.
Watch